Join BOPA
Back to news articles

CRUK Consent Forms – Acalabrutinib, Ibrutinib and Bendamustine-Rituximab

By BOPA Committee on 24th February 2022

A new consent form for Acalabrutinib has been added for CLL. In addition,  Ibrutinib and Bendamustine-Rituximab consent forms have been updated.

They are now available on the CRUK website at: www.cruk.org/sact_consent.

Please share with the members of your organisations and also anyone else who may be interested. 

Any questions please let me know.

Best wishes,

 

Alia Nizam, Specialist Oncology Pharmacist. CRUK – Information Lead

Guy’s and St Thomas’ NHS Foundation Trust

 

Latest News

By BOPA on 27th October 2025

Celebrating Success in the BOPA Immunotherapy Group

The BOPA Immunotherapy Cancer Advisory Group, have recently done some research into immune-related cardiac toxicity; both the monitoring for, and management of, these rare but serious adverse effects. Simon Jenkinson,…

Read article
By BOPA on 27th October 2025

Celebrating Black History Month – Celebrating Excellence with Gisela Abbam

In celebration of Black History Month, the Kingston University BAME staff network  is excited to invite you to an inspiring session with Gisela Abbam,  Chair of the General Pharmaceutical Council (GPhC). Gisela…

Read article
By BOPA Committee on 26th October 2025

Immunotherapy Study Day at Royal Marsden Hospital

The team at the Royal Marsden Hospital are organising an immunotherapy study day on the 3rd December, please see link below for more information. A User Guide to Cancer Immunotherapy…

Read article
By BOPA Committee on 26th October 2025

Collaboration on Reviewing Existing SACT Protocols

Dear BOPA Members, As you may be aware, the National SACT Protocol Project is due to commence shortly in collaboration with the UK SACT Board and the Pharmaceutical Press. The…

Read article